Loading...
The Combination of Immune Checkpoint Blockade and Angiogenesis Inhibitors in the Treatment of Advanced Non-Small Cell Lung Cancer
Immune checkpoint blockade (ICB) has become a standard treatment for non-small cell lung cancer (NSCLC). However, most patients with NSCLC do not benefit from these treatments. Abnormal vasculature is a hallmark of solid tumors and is involved in tumor immune escape. These abnormalities stem from th...
Na minha lista:
| Udgivet i: | Front Immunol |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Frontiers Media S.A.
2021
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8206805/ https://ncbi.nlm.nih.gov/pubmed/34149730 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2021.689132 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|